Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating our understanding of the role of Tissue Factor (TF) into a new therapeutic approach to retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel human fusion protein that addresses the root causes of acute vision loss in AMD. We are currently enrolling a Phase 2 clinical trial. Beyond AMD, Iconic is investigating the ICON family of proteins in cancer. The company is headquartered in South San Francisco, CA.
For more information visit: http://www.iconictherapeutics.com